Digital Patient Monitoring Devices Market By Product (Continuous Glucose Monitoring Devices; Cardiac Monitoring Devices; Blood Pressure Monitoring Devices; Respiratory Monitoring Devices; Multiparameter Monitoring Devices; Weight and Activity Monitoring Devices; Implantable Hemodynamic Monitoring Devices); By Application (Diabetes Management; Cardiovascular Monitoring; Respiratory Disease Monitoring; Post-Operative and Post-Discharge Monitoring; Other Chronic Disease Monitoring); By End User (Home Care Settings, Hospitals, Ambulatory Care Centers, Specialty Clinics, Physician Practices, Long-Term Care and Rehabilitation Facilities); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Digital Patient Monitoring Devices Market: Market Overview and Strategic Context

The Global Digital Patient Monitoring Devices Market was valued at USD 15.95 billion in 2025 and is projected to reach USD 28.21 billion by 2032, growing at a CAGR of 8.5% from 2025 to 2032, according to Strategic Market Research. The forecast represents an absolute revenue increase of USD 12.26 billion and a 76.9% expansion over seven years, taking the market to approximately 1.77 times its 2025 value.

 

The market is moving from stand-alone home devices to connected monitoring platforms. These systems link medical devices with automated data transfer, clinical dashboards and patient-management services. Key products are blood-pressure monitors, continuous glucose monitors, ECG patches, pulse oximeters, implanted cardiac monitors and pulmonary-artery pressure sensors. 

 

Revenue now depends on the monitoring cycle rather than hardware sales alone. Blood-pressure cuffs and scales have long replacement periods. Glucose sensors and ECG patches create recurring demand. Implanted sensors generate procedure revenue followed by fees for connectivity and clinical monitoring. CMS describes remote patient monitoring as the automatic transmission of patient data such as blood pressure, glucose, oxygen saturation and weight to a healthcare provider.

 

Medicare Utilization Confirms a Scalable Commercial Model

U.S. Medicare data provide the clearest evidence of paid utilization. Medicare payments for remote patient monitoring reached USD 536 million in 2024, increasing 31% from 2023. Nearly one million Medicare enrollees received RPM services, representing 27% annual growth, and approximately 4,639 medical practices routinely billed for them.

Connected monitoring has progressed beyond small digital-health pilots into an established reimbursed service involving device setup, data transmission, clinical review, and treatment management. The USD 536 million figure should not be treated as a share of the USD 15.95 billion global market because it measures U.S. reimbursement for monitoring services rather than worldwide device, software, and service revenue.

Commercial insurers, Medicaid programs, integrated delivery networks, Veterans Health Administration programs, employer-sponsored plans, and direct health-system contracts support additional use outside Medicare claims. Hospital-at-home programs, post-discharge services, specialty clinics, and accountable-care organizations may also procure systems through broader care-management budgets.

Reimbursement growth is accompanied by closer oversight. HHS OIG has identified billing patterns requiring scrutiny, including multiple devices billed for the same beneficiary and services initiated without an established relationship between the patient and medical practice. Vendors increasingly need to demonstrate medical necessity, documented consent, reliable data collection, and clinical use of transmitted information.

 

Chronic Disease Burden Expands the Addressable Patient Pool

Hypertension represents the broadest potential population for connected physiological monitoring. Approximately 119.9 million U.S. adults have hypertension, while WHO estimates that 1.4 billion adults aged 30–79 worldwide had the condition in 2024. Around 630 million were diagnosed and receiving treatment. Connected blood-pressure monitoring is relevant where providers require repeated readings for treatment adjustment and evaluation of uncontrolled blood pressure.

OMRON reports more than 400 million cumulative home-use blood-pressure monitor units sold worldwide. The figure demonstrates the scale of the home-monitoring device base, although it includes connected and unconnected products.

Diabetes supports a more mature recurring-device model. CDC estimates that 40.1 million people in the United States had diabetes in 2023, including 29.1 million diagnosed and 11 million undiagnosed individuals. Frequent readings, recurring sensor replacement, and direct use of data in treatment decisions give diabetes monitoring one of the strongest revenue profiles in the market.

Nearly 6.7 million U.S. adults have heart failure, while an NHLBI-supported analysis estimated that at least 10.55 million U.S. adults have atrial fibrillation. These populations create demand for connected weight, blood-pressure, oxygen-saturation, hemodynamic, ECG, mobile telemetry, and implanted-device monitoring.

Approximately 14.2 million U.S. adults had physician-diagnosed COPD in 2021. Respiratory monitoring is mainly used in high-risk, oxygen-dependent, recently hospitalized, or frequently exacerbating populations. Masimo estimates that its SET pulse-oximetry technology monitors more than 200 million patients annually, although this includes institutional monitoring and is not a digital home-monitoring market share.

These disease populations overlap substantially. Epidemiological figures indicate clinical need rather than an additive calculation of commercially eligible patients.

 

Continuous Glucose Monitoring Sets the Commercial Benchmark

Continuous glucose monitoring provides the strongest example of how digital monitoring can become a high-volume medical-device business. Sensors require regular replacement, readings are generated throughout the day, reimbursement pathways are relatively mature, and users remain connected to associated software and analytics platforms.

Abbott reported approximately seven million FreeStyle Libre users and USD 6.8 billion in Diabetes Care revenue for 2024. During the fourth quarter of 2025, Abbott’s continuous glucose-monitor sales reached USD 2.0 billion, increasing 12.2% organically and 15% on a reported basis. Diabetes Care sales grew 11.7% organically during the same quarter.

Dexcom generated USD 4.66 billion in reported revenue during 2025, up 16% from 2024. U.S. revenue increased 15%, while international revenue grew 16%. Fourth-quarter revenue reached USD 1.26 billion, with U.S. sales rising 11% and international sales increasing 18%.

These figures cannot be converted into global shares because Abbott and Dexcom report under different business scopes. They nevertheless show that glucose monitoring accounts for a large portion of disclosed digital-monitoring revenue and is expanding faster than the overall market’s 8.5% forecast CAGR.

Competition is extending beyond sensor accuracy toward wider reimbursement, pharmacy distribution, longer wear periods, interoperability with insulin-delivery systems, consumer-facing products, and access for people with type 2 diabetes who do not use intensive insulin therapy.

 

Cardiac Monitoring Moves Toward Longer and More Actionable Data Capture

Ambulatory cardiac monitoring is developing from short diagnostic recordings into longer-duration, service-based monitoring. Patch ECG products combine a wearable sensor with data processing, algorithm-supported analysis, technician review, and a clinical report.

iRhythm generated USD 747.1 million in 2025 revenue, increasing 26.2% from USD 591.8 million in 2024. Fourth-quarter revenue grew 27.1% to USD 208.9 million, while full-year gross margin increased from 68.9% to 70.6%. Higher Zio service volume was the main growth contributor.

More than one million patients used iRhythm’s next-generation Zio monitor between September 2023 and September 2024. These patients represented nearly 70% of iRhythm’s U.S. long-term continuous-monitoring registrations during the period, not 70% of the overall U.S. ambulatory ECG market.

Longer monitoring periods improve the likelihood of detecting intermittent arrhythmias that may not appear during a 24- or 48-hour Holter examination. Remote monitoring of implanted cardiac devices adds recurring revenue through platforms such as Medtronic CareLink and Boston Scientific LATITUDE NXT, although vendors must control alert burden and ensure clinically relevant information reaches the appropriate provider.

 

Implantable Monitoring Supports a Smaller High-Value Segment

Implantable pulmonary-artery pressure monitoring addresses selected heart-failure patients at elevated risk of hospitalization. These systems require catheter-based implantation, specialist involvement, regulatory approval, and long-term clinical follow-up.

FDA approved the Cordella Pulmonary Artery Sensor System in June 2024 for selected New York Heart Association Class III heart-failure patients receiving guideline-directed medical therapy. Abbott’s CardioMEMS established the earlier commercial pathway, while Edwards Lifesciences entered the segment through its acquisition of Endotronix and Cordella.

Implantable monitoring remains far smaller by patient volume than glucose, blood-pressure, or external ECG monitoring. Higher device prices, procedure involvement, specialist care, and recurring clinical services nevertheless make it an important premium subsegment.

 

Shorter Monitoring Periods Broaden Reimbursement Eligibility

Medicare’s 2026 framework recognizes remote physiological data collection for either 2–15 days or at least 16 days within a 30-day period, depending on the billing code. The shorter-duration pathway can improve reimbursement suitability for episodic conditions, post-discharge programs, and protocols that do not require a complete month of data.

Remote therapeutic monitoring also gained codes covering 2–15 days of respiratory or musculoskeletal monitoring and a new treatment-management code covering the first ten minutes of clinician time. These revisions expand the commercial space for connected respiratory devices, rehabilitation tools, adherence systems, and monitoring tied to treatment response.

 

Outcome-Based Payment Creates a New Purchasing Model

CMS launched the ACCESS Model in July 2026 as a ten-year national test of outcome-aligned payment for technology-supported chronic care. Its initial focus includes high blood pressure, diabetes, chronic musculoskeletal pain, and depression—conditions affecting more than two-thirds of Medicare beneficiaries.

ACCESS could shift purchasing decisions from the price of an individual device toward the cost of achieving a clinical result. Suppliers may need to support medication management, patient engagement, clinician coordination, and outcome reporting rather than selling a stand-alone sensor or dashboard.

 

Cybersecurity and Workflow Capacity Become Procurement Barriers

Connected monitoring increases the volume of health information moving between patient devices, mobile applications, cloud platforms, and provider systems. Cybersecurity, software maintenance, secure data transmission, and post-market vulnerability management are becoming procurement requirements rather than secondary information-technology concerns.

A system generating excessive alerts or requiring repeated manual review can increase staffing costs despite reducing face-to-face visits. Purchasing decisions increasingly consider electronic health-record integration, onboarding, connectivity, reporting quality, alert prioritization, and the proportion of readings that result in a clinical action.

 

Market Segmentation Insights

The following shares and CAGRs are Strategic Market Research modeled estimates aligned with the USD 15.95 billion market in 2025 and USD 28.21 billion forecast for 2032.

Connected and Wearable Devices Lead Patient Volume

Connected and wearable monitoring devices accounted for an estimated 57.0% of revenue in 2025 and are projected to grow at a 9.2% CAGR through 2032. Continuous glucose monitors, ECG patches, blood-pressure monitors, pulse oximeters, and connected scales support broad home and outpatient deployment.

Continuous and real-time monitoring represented an estimated 54.5% share and is expected to expand at a 9.5% CAGR. Devices and sensors remained the largest component with a 61.5% share, while software, connectivity, and clinical platforms accounted for 23.0% and are projected to record the fastest component CAGR of 10.6%. Bluetooth and smartphone-connected devices held an estimated 45.0% connectivity share, while cellular-connected devices and hubs are expected to grow fastest at 9.6%.

Abbott’s seven million Libre users, Dexcom’s USD 4.66 billion in 2025 revenue, OMRON’s more than 400 million cumulative home blood-pressure monitor sales, and Masimo’s more than 200 million patients monitored annually confirm the segment’s scale, although these metrics are not directly comparable market shares.

 

Diabetes Management Anchors Recurring Revenue

Diabetes monitoring accounted for an estimated 38.0% market share in 2025 and is projected to grow at a 9.3% CAGR through 2032. Abbott’s USD 2.0 billion fourth-quarter 2025 CGM sales and Dexcom’s 16% full-year revenue growth indicate expansion above the overall market’s 8.5% CAGR.

Cardiovascular monitoring represented an estimated 27.5% share and is also projected to grow at approximately 9.3% CAGR. iRhythm’s 26.2% revenue growth supports demand for long-duration ECG services, while implanted cardiac-device platforms generate recurring data-transmission activity.

Hypertension monitoring held an estimated 13.5% share and is forecast to grow at 6.7%. Respiratory monitoring represented approximately 8.5% and is expected to expand at 7.9%, while post-operative and other monitoring applications accounted for 12.5% and are projected to grow at 6.2%.

 

Home Care Becomes the Primary Monitoring Environment

Home care and patient-residence monitoring accounted for an estimated 48.0% of revenue in 2025 and is projected to grow at the fastest end-user CAGR of 9.9%. Hospitals represented approximately 29.5%, while ambulatory clinics and physician practices accounted for 15.5%.

Hospitals remain important purchasers for discharge-transition, implantable cardiac, acute deterioration, and hospital-at-home programs. Most readings, however, are generated in the patient’s home and reviewed by outpatient clinics, specialty practices, monitoring centers, or centralized care teams.

 

North America Retains the Strongest Commercial Infrastructure

North America accounted for an estimated 42.5% of global revenue in 2025 and is projected to grow at a 7.7% CAGR. Medicare reimbursement, private insurance coverage, established device companies, high chronic-disease prevalence, and substantial CGM and ambulatory ECG utilization support its leading position.

Europe represented an estimated 26.0% share and is expected to grow at 7.6%. Asia-Pacific accounted for approximately 23.0% and is projected to record the fastest regional CAGR of 11.0%, supported by diabetes-device adoption, healthcare digitization, local manufacturing, and connected-care investment. Latin America represented around 5.0%, while the Middle East & Africa accounted for approximately 3.5%.

 

Competitive Landscape

The competitive structure brings together diversified medical-device companies and specialized monitoring businesses. Abbott and Dexcom hold substantial positions in CGM. OMRON Healthcare participates in connected blood-pressure monitoring. iRhythm and Philips operate in ambulatory cardiac monitoring, while Medtronic and Boston Scientific support implanted cardiac-device monitoring. Masimo competes in pulse oximetry and hospital-to-home physiological monitoring. Abbott and Edwards Lifesciences participate in implantable heart-failure monitoring.

Competition increasingly centers on patient access, reimbursement, clinical workflow, recurring service economics, regulatory evidence, cybersecurity, and the ability to demonstrate reduced acute-care utilization. Differences in reporting scope prevent a reliable ranking of total company market shares.

 

Market Outlook

The Global Digital Patient Monitoring Devices Market is expected to expand from USD 15.95 billion in 2025 to USD 28.21 billion by 2032 at an 8.5% CAGR. Medicare RPM payments are already growing at 31%, Dexcom increased 2025 revenue by 16%, iRhythm expanded by 26.2%, and Abbott’s fourth-quarter CGM sales rose 12.2% organically. These rates indicate that recurring glucose, cardiac, software, and home-monitoring segments are likely to capture a greater portion of incremental revenue.

Near-term growth will remain concentrated in CGM, ambulatory cardiac monitoring, connected blood-pressure programs, pulse oximetry, and remote management of implanted cardiovascular devices. Respiratory monitoring, post-operative recovery, rehabilitation, and broader multimorbidity programs offer additional opportunity, although their reimbursement and clinical workflows remain less standardized.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 15.95 Billion
Revenue Forecast in 2032	USD 28.21 Billion
Overall Growth Rate	CAGR of 8.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Continuous Glucose Monitoring Devices; Cardiac Monitoring Devices [Ambulatory ECG Patches, Mobile Cardiac Telemetry Devices, Implantable Cardiac Monitoring Devices]; Blood Pressure Monitoring Devices; Respiratory Monitoring Devices [Pulse Oximeters, Connected Spirometers]; Multiparameter Monitoring Devices; Weight and Activity Monitoring Devices; Implantable Hemodynamic Monitoring Devices
By Application	Diabetes Management; Cardiovascular Monitoring [Arrhythmia Monitoring, Heart Failure Monitoring, Hypertension Monitoring]; Respiratory Disease Monitoring; Post-Operative and Post-Discharge Monitoring; Other Chronic Disease Monitoring
By End User	Home Care Settings, Hospitals, Ambulatory Care Centers, Specialty Clinics, Physician Practices, Long-Term Care and Rehabilitation Facilities
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising chronic disease burden, expanding adoption of connected and wearable monitoring devices, growing demand for home-based and post-discharge care, increasing integration of real-time patient data with digital health platforms
Customization Option	Available upon request